Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

9.750 -0.090 (-0.91%)
Streaming Delayed Price Updated: 12:52 PM EDT, Oct 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,709
Open 9.970
Bid (Size) 9.660 (1)
Ask (Size) 9.860 (1)
Prev. Close 9.840
Today's Range 9.660 - 9.985
52wk Range 3.760 - 46.80
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025
Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184 
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
From Aligos Therapeutics
Via GlobeNewswire

Performance

YTD
-75.5%
-75.5%
1 Month
-12.2%
-12.2%
3 Month
+18.3%
+18.3%
6 Month
+107.0%
+107.0%
1 Year
+30.0%
+30.0%

More News

Read More
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Aligos Therapeutics
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Aligos Therapeutics's Earnings Outlook
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Data at APASL 2025
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Aligos Therapeutics, Inc. - Common stock publicly traded?
Yes, Aligos Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Aligos Therapeutics, Inc. - Common stock trade on?
Aligos Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aligos Therapeutics, Inc. - Common stock?
The ticker symbol for Aligos Therapeutics, Inc. - Common stock is ALGS on the Nasdaq Stock Market
What is the current price of Aligos Therapeutics, Inc. - Common stock?
The current price of Aligos Therapeutics, Inc. - Common stock is 9.750
When was Aligos Therapeutics, Inc. - Common stock last traded?
The last trade of Aligos Therapeutics, Inc. - Common stock was at 10/08/25 12:52 PM ET
What is the market capitalization of Aligos Therapeutics, Inc. - Common stock?
The market capitalization of Aligos Therapeutics, Inc. - Common stock is 418.67M
How many shares of Aligos Therapeutics, Inc. - Common stock are outstanding?
Aligos Therapeutics, Inc. - Common stock has 419M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.